Overview
NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in adults. This is because Roche Products did not provide an evidence submission.
Last reviewed: 12 March 2025
Next review: We will review this decision if the company decides to make an evidence submission.